Alnylam Pharmaceuticals/ALNY

$148.50

-2.68%
-
1D1W1MYTD1YMAX

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Ticker

ALNY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Yvonne Greenstreet

Employees

2,100

Headquarters

Cambridge, United States

ALNY Metrics

BasicAdvanced
$18.7B
Market cap
-
P/E ratio
-$3.59
EPS
0.40
Beta
-
Dividend rate
$18.7B
0.39758
$218.88
$143.52
842.55K
3.082
2.99
-2.11%
-11.94%
-15.61%
10.229
445.85
76.23%
61.39%
54.8%

What the Analysts think about ALNY

Analyst Ratings

Majority rating from 28 analysts.
Buy

Price Targets

Average projection from 22 analysts.
49.95% upside
High $395.00
Low $136.00
$148.50
Current price
$222.68
Average price target

ALNY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-31.33% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$439.7M
-41.41%
Net income
$-137.8M
-193.3%
Profit margin
-31.33%
-259.2%

ALNY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.40
-$2.21
$1.15
-$1.10
-
Expected
-$1.77
-$1.37
-$1.34
-$1.32
-$1.18
Surprise
-20.68%
61.47%
-186.09%
-16.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals (ALNY) has a market cap of $18.7B as of April 15, 2024.

What is the P/E ratio for Alnylam Pharmaceuticals stock?

The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of April 15, 2024.

Does Alnylam Pharmaceuticals stock pay dividends?

No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Alnylam Pharmaceuticals dividend payment date?

Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.

What is the beta indicator for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Alnylam Pharmaceuticals stock price target?

The target price for Alnylam Pharmaceuticals (ALNY) stock is $222.68, which is 49.95% above the current price of $148.5. This is an average based on projections from 22 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alnylam Pharmaceuticals stock

Buy or sell Alnylam Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing